908 Devices Reports First Quarter 2025 Financial Results and Reiterates 2025 Revenue Outlook
RGEN Stock | USD 115.88 0.62 0.53% |
About 62% of Repligen's investor base is looking to short. The analysis of overall sentiment of trading Repligen stock suggests that many investors are alarmed at this time. Repligen's investing sentiment overview a quick insight into current market opportunities from investing in Repligen. Many technical investors use Repligen stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
BOSTON, May 13, 2025--908 Devices Inc. a core small-cap growth company focused on purpose-built handheld chemical analysis tools for vital health, safety and defense tech applications, today reported financial results for the quarter ended March 31, 2025.
Read at finance.yahoo.com
![]() |
Repligen Fundamental Analysis
We analyze Repligen's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Repligen using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Repligen based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Current Asset
Current Asset Comparative Analysis
Repligen is currently under evaluation in current asset category among its peers. Current Asset is all of the company's assets that can be used to pay off current liabilities within the current fiscal period or over the next 12 months. Current Asset includes cash or cash equivalents, accounts receivable, short-term investments, and the portion of prepaid liabilities which will be paid within the next 12 months. Because these assets are easily turned into cash, they are sometimes referred to as liquid assets.
Repligen Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Repligen stock to make a market-neutral strategy. Peer analysis of Repligen could also be used in its relative valuation, which is a method of valuing Repligen by comparing valuation metrics with similar companies.
Peers
Repligen Related Equities
BDX | Becton Dickinson | 1.43 | ||||
ANGO | AngioDynamics | 1.29 | ||||
HOLX | Hologic | 1.12 | ||||
COO | Cooper Companies, | 0.82 | ||||
WST | West Pharmaceutical | 0.20 | ||||
HAE | Haemonetics | 0.25 | ||||
ICUI | ICU Medical | 0.80 | ||||
MMSI | Merit Medical | 1.04 | ||||
TFX | Teleflex Incorporated | 1.04 | ||||
ISRG | Intuitive Surgical | 1.32 | ||||
ATR | AptarGroup | 1.57 | ||||
NVST | Envista Holdings | 2.00 | ||||
RMD | ResMed | 2.21 |
Check out Repligen Hype Analysis, Repligen Correlation and Repligen Performance. To learn how to invest in Repligen Stock, please use our How to Invest in Repligen guide.You can also try the Share Portfolio module to track or share privately all of your investments from the convenience of any device.
Is Pharmaceutical Products space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Repligen. If investors know Repligen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Repligen listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Repligen is measured differently than its book value, which is the value of Repligen that is recorded on the company's balance sheet. Investors also form their own opinion of Repligen's value that differs from its market value or its book value, called intrinsic value, which is Repligen's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Repligen's market value can be influenced by many factors that don't directly affect Repligen's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Repligen's value and its price as these two are different measures arrived at by different means. Investors typically determine if Repligen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Repligen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.